A Clinician-Oriented Guide to Diagnosis, Pharmacotherapy, and Functional Medicine Considerations

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Introduction: Why Hyperadrenergic POTS Matters

Postural orthostatic tachycardia syndrome (POTS) affects an estimated 1 to 3 million Americans, and the number of recognized cases has expanded significantly in the years following the COVID-19 pandemic. Within this population, a subset of clients experience what clinicians refer to as hyperadrenergic POTS — a phenotype characterized by excessive sympathetic nervous system activation that goes beyond the orthostatic heart rate changes seen in standard POTS presentations.

These clients often describe a constellation of distressing symptoms: pounding heart, visible tremulousness, drenching sweats, facial flushing, and sometimes dramatic blood pressure surges upon standing. The experience can be frightening. Many have been told their symptoms are anxiety or panic disorder before the autonomic physiology is ever investigated.

The clinical stakes here are significant. Hyperadrenergic POTS is not simply "POTS with high adrenaline." The underlying mechanism — whether the sympathetic overdrive is a primary central nervous system phenomenon or a compensatory response to low blood volume, venous pooling, or peripheral neuropathy — directly determines which treatments will help and which will make the client worse. Suppressing a compensatory adrenergic surge too aggressively can worsen orthostatic tolerance and provoke near-syncope or frank syncope.

This article walks through the clinical approach step by step: establishing the POTS diagnosis, identifying the hyperadrenergic phenotype, reviewing the pharmacotherapy evidence including the recent Vanderbilt guanfacine data, and describing an integrative approach that prioritizes treating what can actually be measured and demonstrated over speculative models.

Establishing the POTS Diagnosis First

Before anyone should be labeled "hyperadrenergic POTS," the foundational POTS diagnosis itself needs to be established with rigor. The diagnostic criteria are well defined, and skipping or shortcutting them leads to both missed diagnoses and misdiagnoses.

All of the following must be present:

• Sustained orthostatic tachycardia: a heart rate increase of at least 30 beats per minute in adults (or 40 beats per minute in adolescents aged 12 to 19) within 10 minutes of standing or upright tilt — and this increase must be sustained on at least two separate readings taken at least one minute apart.

• No qualifying orthostatic hypotension: the blood pressure must not show a sustained drop meeting the 20/10 mmHg threshold that would indicate classic orthostatic hypotension.

• Chronic orthostatic symptoms: lightheadedness, palpitations, weakness, tremulousness, blurred vision, or fatigue that consistently improve with lying down.

• Duration of at least three months.

• No alternative diagnosis that better explains the findings.

A common misconception is that POTS requires a standing heart rate above 120 beats per minute. It does not. The criterion is the magnitude of the heart rate increase, not the absolute number.

The Office Assessment

A proper in-office assessment involves:

• Having the client rest supine for 5 to 10 minutes in a quiet environment.

• Recording baseline supine heart rate and blood pressure.

• Taking repeat measurements at 1, 3, 5, 8, and 10 minutes of standing.

• Documenting symptoms at each measurement point.

• Confirming that the qualifying heart rate rise is sustained — not a transient spike from standing up too quickly.

If the initial study is negative but clinical suspicion remains high, consider repeating it in the morning hours when symptoms are often more pronounced. Tilt-table testing remains useful when the office assessment is equivocal or when a more detailed autonomic evaluation is warranted.

Initial Testing and Differential Diagnosis

Before attributing everything to POTS, a core evaluation should include an ECG, CBC with hemoglobin, comprehensive metabolic panel, ferritin, TSH, and morning cortisol. Review the client's hydration status, any recent blood loss, all medications and supplements, and stimulant exposure including caffeine.

The differential diagnosis includes anemia, dehydration, hyperthyroidism, adrenal insufficiency, medication side effects, inappropriate sinus tachycardia, and supraventricular tachycardia. When episodes feature abrupt onset and offset rather than a consistent positional pattern, arrhythmia evaluation takes priority. Pheochromocytoma, while uncommon, belongs in the differential when the clinical picture warrants it.

Identifying the Hyperadrenergic Phenotype

Once POTS is confirmed, the next clinical question is whether the pattern reflects genuine central sympathetic overactivity or whether the elevated catecholamines are the body's appropriate — even necessary — response to low circulating volume, venous pooling, or peripheral autonomic neuropathy.

This distinction is not academic. It is the most consequential clinical decision in treating these clients. Getting it wrong means either withholding a helpful sympatholytic medication or, worse, suppressing a compensatory mechanism that the client needs to remain upright.

Upright Norepinephrine

An upright plasma norepinephrine level of approximately 600 pg/mL or higher is frequently cited as a supportive marker for the hyperadrenergic phenotype. However, this number must be interpreted carefully:

• Testing requires standardized supine and upright blood draws after appropriate rest periods and attention to medications and hydration status that can affect results.

• An isolated, non-standardized catecholamine level drawn during a clinic visit is difficult to interpret meaningfully.

• Critically, norepinephrine above 600 pg/mL can also reflect volume depletion and a compensatory adrenergic response. A high standing norepinephrine does not, by itself, prove that the client needs a drug to suppress sympathetic activity.

Blood Pressure Patterns

An upright blood pressure increase and hypertensive episodes during symptomatic flares add to clinical suspicion but are not individually diagnostic. Some clients with classic hyperadrenergic physiology maintain normal blood pressure, while others with volume-mediated POTS can exhibit transient pressure surges.

Emerging Autonomic Laboratory Markers

The 2024 Vanderbilt Autonomic Dysfunction Center research identified a potentially useful physiologic marker: an exaggerated diastolic blood pressure response during phase II of the Valsalva maneuver. Specifically:

• The relevant measurement was the rise from early to late phase II — not a simple standing blood pressure reading.

• A diastolic BP rise greater than 17 mmHg during this phase identified clients with the highest resting sympathetic activity with 71% sensitivity and 85% specificity.

• This marker showed correlation with treatment response to guanfacine in the treatment cohort.

This is a promising development, but it remains an emerging phenotyping tool — not yet a universally validated or widely available diagnostic requirement. It does, however, point the field toward a more physiologically precise way of identifying who is most likely to benefit from centrally acting sympatholytic therapy.

Guanfacine: The Vanderbilt Evidence and What It Actually Shows

An important clarification before diving into this section: the drug is guanfacine (a centrally acting alpha-2 adrenergic agonist), not guaifenesin (an over-the-counter expectorant). These are different medications with completely different mechanisms. The confusion surfaces regularly in online POTS communities, and it matters clinically.

What the 2024 Vanderbilt Study Found

The study published in Hypertension included two components:

• A physiologic phenotyping cohort of 28 clients with hyperadrenergic POTS, which characterized the Valsalva-based biomarker described above.

• An uncontrolled treatment cohort of 38 clients who received guanfacine. Among those who met the study's hyperadrenergic biomarker criteria, 85% reported clinical improvement compared to 44% of those without the biomarker.

The biomarker-positive group also showed improvements in orthostatic tolerance, fatigue, and functional measures — not just subjective symptom scores.

What this is: the strongest published signal to date that guanfacine can be selectively effective in a physiologically defined subgroup of hyperadrenergic POTS.

What this is not: a randomized, placebo-controlled efficacy trial. Selection effects, concurrent treatments, and self-reported outcome measures limit how confidently the 85% improvement figure can be generalized. This number should not be presented to clients as a reliable prediction of their individual response.

Dosing Framework

Other Pharmacotherapy Options

Beyond guanfacine, several medications address different components of the hyperadrenergic POTS physiology. These are alternatives or carefully considered combinations — not a regimen to start simultaneously.

Propranolol

A nonselective beta blocker that directly reduces adrenergic tachycardia. Published POTS dosing typically begins at 10 to 20 mg up to four times daily. An underappreciated clinical point: in POTS, lower doses often work better than higher ones. Higher doses can worsen fatigue, exercise intolerance, and orthostatic symptoms. Watch for bradycardia, hypotension, fatigue, and bronchospasm.

Ivabradine

A selective sinus node inhibitor that reduces heart rate without the blood pressure effects of beta blockers. Published POTS dosing typically starts at 5 mg twice daily, though individualized lower dosing may be appropriate. Ivabradine has the strongest experimental evidence in hyperadrenergic POTS specifically — a 22-participant randomized crossover trial demonstrated improved heart rate control and quality-of-life outcomes versus placebo. That trial remains small and short-term, but it provides a higher level of evidence than the uncontrolled Vanderbilt guanfacine series. Ivabradine is particularly useful when blood pressure limitations prevent the use of other agents.

Clonidine

Another centrally acting alpha-2 agonist that reduces sympathetic outflow. Published dosing ranges from 0.1 to 0.2 mg two to three times daily or via a transdermal patch; starting doses are typically lower. Clonidine shares the same mechanism as guanfacine but tends to produce more sedation, dry mouth, and hypotension. Rebound hypertension with missed doses or abrupt withdrawal is a clinically important risk.

Methyldopa

A central sympatholytic occasionally used when other agents are not tolerated. One clinical review begins at 125 mg at bedtime, advancing to 125 mg twice daily if tolerated. Fatigue, cognitive fog, hypotension, and mood effects can all limit its utility.

Pyridostigmine

A cholinesterase inhibitor that may reduce upright tachycardia, particularly in clients with mixed autonomic physiology. Published dosing ranges from 30 to 60 mg up to three times daily. The main limitation is gastrointestinal side effects — increased bowel motility can be problematic in clients who already have diarrhea-predominant symptoms, which is common in the POTS/MCAS overlap population.

A Note on Midodrine and Fludrocortisone

These agents are standard treatments for many POTS clients but are not automatic choices in the hyperadrenergic phenotype. Midodrine raises blood pressure through peripheral vasoconstriction, and fludrocortisone expands volume through sodium retention — both of which can exacerbate hypertensive episodes in a client whose primary problem is central sympathetic overactivity rather than low circulating volume. However, when the clinical picture includes clear evidence of hypovolemia, venous pooling, or hypotension between adrenergic surges, these agents may still play a carefully titrated role. Fludrocortisone requires potassium monitoring.

An Evidence-Based Integrative Approach

The integrative approach that holds up to scrutiny here is straightforward: identify and treat what can actually be measured, demonstrated, and modulated — rather than imposing a speculative explanatory model onto a complex autonomic syndrome.

Volume Restoration — Individualized, Not Formulaic

Standard POTS guidance recommends approximately 3 liters of fluid daily and increased dietary sodium. A small crossover study demonstrated that higher sodium intake expanded plasma volume and reduced both upright norepinephrine and heart rate — illustrating that what looks like "too much adrenaline" can partly be the body's response to not enough circulating volume.

For hyperadrenergic clients, however, this must be individualized. A blanket high-salt protocol applied to someone with sustained hypertension or blood pressure surges on standing can worsen those surges. Fluid and sodium targets should be calibrated to supine and upright blood pressure readings, renal function, edema status, and cardiac evaluation.

Compression — Include the Abdomen

Waist-high compression garments or combined abdominal plus lower-extremity compression improve venous return and reduce orthostatic tachycardia. The evidence favors including the abdomen — knee-high compression stockings alone are unlikely to produce meaningful hemodynamic improvement. This approach addresses circulation without directly suppressing the sympathetic response, making it valuable regardless of whether the adrenergic activation is primary or compensatory.

Graduated Exercise — Screen for PEM First

Structured exercise rehabilitation, particularly beginning with non-upright or recumbent conditioning (rowing, recumbent cycling, swimming), can improve cardiovascular physiology and reduce symptom burden in POTS. The Levine/CHOP protocols are widely referenced.

However, before prescribing any exercise program, screen for post-exertional malaise (PEM). Many clients with POTS — particularly those with long COVID or concurrent ME/CFS — experience delayed symptom worsening 12 to 48 hours after exertion. For these clients, pushing through symptoms or imposing automatic exercise escalation can provoke prolonged clinical deterioration. Pacing and energy management strategies must take priority over cardiovascular conditioning when PEM is present.

Correct Demonstrated Deficiencies — Not Speculative Ones

Check for and address iron deficiency (ferritin is part of the recommended core assessment), anemia, thyroid dysfunction, electrolyte abnormalities, and inadequate nutritional intake. Treating an actual contributor is more defensible — and more effective — than layering on a broad supplement stack without documented evidence of need.

This is where functional medicine adds genuine value: a thorough nutritional evaluation, testing that goes beyond a basic panel when the clinical picture warrants it, and targeted repletion of demonstrated deficiencies. It is also where functional medicine occasionally overreaches — when an elaborate testing panel is ordered not because of specific clinical findings but because it fits a predetermined explanatory framework.

Review Medications and Supplements That Amplify Symptoms

Stimulant medications, norepinephrine-reuptake inhibitors (including some antidepressants), diuretics, and certain supplements can exacerbate orthostatic tachycardia and adrenergic symptoms. Review the complete medication and supplement list — including OTC products, energy drinks, and herbal preparations — before escalating treatment. Medication changes require balancing the indication for the original drug against its autonomic effects; this is a conversation, not a unilateral discontinuation.

Mast Cell Evaluation — When It Is and Is Not Warranted

The POTS/MCAS overlap is real and clinically important. When POTS episodes include flushing, urticaria, wheezing, or prominent gastrointestinal symptoms, mast cell activation syndrome should be investigated.

But flushing and tachycardia alone do not establish mast cell disease. The Vanderbilt research found that clinically similar flushing episodes occurred in their hyperadrenergic POTS cohort without documented mast cell activation. This is an important distinction, because attributing symptoms to MCAS that are actually driven by central sympathetic overactivity leads to a treatment path that misses the underlying physiology.

When MCAS is appropriately diagnosed or strongly suspected, specialist-directed options include H1/H2 antihistamines, cromolyn sodium, and other mediator-directed treatments. Evidence that these treatments improve POTS itself — as opposed to the mast cell symptoms co-occurring with POTS — remains limited.

Where Functional Medicine Claims Exceed the Evidence

An honest clinical article on this topic must address where popular functional medicine frameworks outrun the available data. The reviewed clinical guidance and published studies do not establish the following as treatments for central hyperadrenergic POTS:

• Guaifenesin protocols (the expectorant — this confusion circulates widely in online POTS communities)

• "Adrenal support" supplement stacks — hyperadrenergic POTS is not adrenal fatigue

• Microbiome-directed supplement regimens — while gut dysfunction is common in POTS, broad probiotic or antimicrobial protocols have not been demonstrated to treat the autonomic phenotype

• "Detoxification" protocols — without a documented toxicant exposure, these lack a clinical indication

Similarly, the presence of postviral onset, gastrointestinal symptoms, or autoimmune markers does not by itself prove a specific infectious, microbiome, or autoimmune mechanism that requires its own treatment. The role of cardiovascular receptor autoantibodies in POTS physiology remains an active area of research but is not yet clinically actionable for most practitioners.

An evidence-conscious approach should clearly distinguish between:

• Treatments supported by controlled POTS studies (even small ones)

• Physiologically reasonable measures supported by smaller or uncontrolled evidence

• Treatment of an independently established comorbidity (e.g., documented iron deficiency, confirmed MCAS)

• Experimental or anecdotal approaches without demonstrated POTS benefit

Clients deserve to know which category their treatment falls into.

Practical Clinical Pathway

Pulling it all together, here is the sequence that makes physiologic sense:

• Step 1: Confirm positional sinus tachycardia and chronic orthostatic symptoms meeting POTS criteria.

• Step 2: Exclude secondary causes and conduct a thorough medication/supplement review.

• Step 3: Document the blood pressure pattern — does it rise, fall, or remain stable during upright symptoms?

• Step 4: Start individualized volume support, compression therapy, and activity management (with PEM screening).

• Step 5: Obtain standardized catecholamines and/or formal autonomic testing when the result would meaningfully change treatment decisions.

• Step 6: For convincing central hyperadrenergic physiology, consider low-dose guanfacine or another sympatholytic. For predominant tachycardia without clear central overdrive, consider low-dose propranolol or ivabradine.

• Step 7: Reassess function and orthostatic tolerance — not just heart rate numbers — and reduce any treatment that worsens fatigue, hypotension, or presyncope.

Monitoring Parameters

Track these at every follow-up visit:

• Supine and standing heart rate and blood pressure

• Episode frequency and severity

• Presyncope or syncope events

• Upright activity tolerance (can they shop, cook, shower without symptoms?)

• Fatigue and cognitive function

• Medication side effects and tolerability

Conclusion: Evidence Over Ideology

Hyperadrenergic POTS is a real and often disabling condition that responds to treatment — when the treatment matches the physiology. The Vanderbilt guanfacine data represents the most significant pharmacotherapeutic advance for this phenotype in recent years, and it points toward a future where autonomic biomarkers guide treatment selection rather than trial-and-error prescribing.

The integrative contribution that genuinely helps these clients is meticulous attention to modifiable contributors — volume status, compression, graded activity, nutritional deficiencies, medication review, and appropriate mast cell evaluation — layered onto a foundation of solid autonomic diagnosis. What does not help is imposing an explanatory model onto the physiology before the physiology has been properly characterized.

Our clients with hyperadrenergic POTS have often spent months or years being told their symptoms are psychological, or conversely, being given elaborate but unvalidated treatment protocols based on assumptions rather than data. They deserve better than either extreme. They deserve clinicians who will take their symptoms seriously, investigate the mechanism rigorously, and treat what the evidence supports — while being transparent about what remains uncertain.

That is what evidence-based integrative medicine looks like in practice.

References

1. Biaggioni I, et al. Hyperadrenergic postural tachycardia syndrome: pathophysiology and guanfacine treatment. Hypertension. 2024. doi:10.1161/HYPERTENSIONAHA.124.23035

2. Raj SR, et al. Diagnosis and management of postural orthostatic tachycardia syndrome. CMAJ. 2022;194(10):E378-E385.

3. Taub PR, et al. Randomized trial of ivabradine in patients with hyperadrenergic postural tachycardia syndrome. J Am Coll Cardiol. 2021;77(7):861-871.

4. Grubb BP. Postural tachycardia syndrome. Cleveland Clinic Journal of Medicine. 2019;86(5):333-344.

5. Vanderbilt Autonomic Dysfunction Center. Treatment approaches for postural tachycardia syndrome. VUMC Clinical Resources. 2024.

6. Centers for Disease Control and Prevention. Treating ME/CFS: Managing the most disruptive symptoms. Updated 2024.

7. National Institutes of Health DailyMed. Guanfacine prescribing information.

8. Mayo Clinic. Guaifenesin — oral route: drug description. (Included for clarification of guaifenesin vs. guanfacine distinction.)

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon

Founder of the LDN Support Group

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com